CA2963110A1 - Methode d'administration de sulfate de chrome et de magnesium en vue du traitement de l'acnee - Google Patents

Methode d'administration de sulfate de chrome et de magnesium en vue du traitement de l'acnee Download PDF

Info

Publication number: CA2963110A1
Authority: CA; Canada
Prior art keywords: acne; composition; skin; area; chromium
Prior art date: 2016-09-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA2963110A

Other languages

English (en)

Inventor

Kenneth O. Russell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-09-06

Filing date

2017-04-04

Publication date

2018-03-06

2016-09-06 Priority claimed from US15/257,861 external-priority patent/US9642877B1/en

2017-04-04 Application filed by Individual filed Critical Individual

2018-03-06 Publication of CA2963110A1 publication Critical patent/CA2963110A1/fr

Status Pending legal-status Critical Current

Links

206010000496 acne Diseases 0.000 title claims abstract description 60
208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 53
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 title claims abstract description 38
238000000034 method Methods 0.000 title claims abstract description 27
229910052943 magnesium sulfate Inorganic materials 0.000 title claims abstract description 19
235000019341 magnesium sulphate Nutrition 0.000 title claims abstract description 19
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 title abstract description 32
229910052804 chromium Inorganic materials 0.000 title abstract description 32
239000011651 chromium Substances 0.000 title abstract description 32
238000011282 treatment Methods 0.000 title abstract description 31
239000000203 mixture Substances 0.000 claims abstract description 58
230000003902 lesion Effects 0.000 claims description 18
230000002757 inflammatory effect Effects 0.000 claims description 17
239000006210 lotion Substances 0.000 claims description 11
230000000694 effects Effects 0.000 claims description 6
239000006071 cream Substances 0.000 claims description 4
208000031513 cyst Diseases 0.000 claims description 4
239000000499 gel Substances 0.000 claims description 3
230000003203 everyday effect Effects 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
238000011200 topical administration Methods 0.000 claims description 2
229910021556 Chromium(III) chloride Inorganic materials 0.000 claims 2
QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 claims 2
235000007831 chromium(III) chloride Nutrition 0.000 claims 2
239000011636 chromium(III) chloride Substances 0.000 claims 2
206010000501 Acne conglobata Diseases 0.000 claims 1
206010049141 Acne fulminans Diseases 0.000 claims 1
208000001348 Chloracne Diseases 0.000 claims 1
206010011732 Cyst Diseases 0.000 claims 1
208000006311 Pyoderma Diseases 0.000 claims 1
238000005406 washing Methods 0.000 claims 1
210000003491 skin Anatomy 0.000 abstract description 24
230000000699 topical effect Effects 0.000 abstract description 11
210000002374 sebum Anatomy 0.000 abstract description 10
210000004927 skin cell Anatomy 0.000 abstract description 9
102000011782 Keratins Human genes 0.000 abstract description 7
108010076876 Keratins Proteins 0.000 abstract description 7
238000004519 manufacturing process Methods 0.000 abstract description 5
230000002401 inhibitory effect Effects 0.000 abstract description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 15
230000006872 improvement Effects 0.000 description 13
238000009472 formulation Methods 0.000 description 12
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
210000001732 sebaceous gland Anatomy 0.000 description 9
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
241000894006 Bacteria Species 0.000 description 6
238000011156 evaluation Methods 0.000 description 6
241000186427 Cutibacterium acnes Species 0.000 description 5
102000004877 Insulin Human genes 0.000 description 5
108090001061 Insulin Proteins 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000002354 daily effect Effects 0.000 description 5
229940125396 insulin Drugs 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 4
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
229910052742 iron Inorganic materials 0.000 description 4
239000011148 porous material Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
229940031439 squalene Drugs 0.000 description 4
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 4
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010037888 Rash pustular Diseases 0.000 description 3
230000002411 adverse Effects 0.000 description 3
235000021588 free fatty acids Nutrition 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
238000005502 peroxidation Methods 0.000 description 3
208000029561 pustule Diseases 0.000 description 3
230000004044 response Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
208000032544 Cicatrix Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010015150 Erythema Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
206010033733 Papule Diseases 0.000 description 2
206010040880 Skin irritation Diseases 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
210000004919 hair shaft Anatomy 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
229960005280 isotretinoin Drugs 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
229940127249 oral antibiotic Drugs 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229940055019 propionibacterium acne Drugs 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
230000037387 scars Effects 0.000 description 2
230000036556 skin irritation Effects 0.000 description 2
231100000475 skin irritation Toxicity 0.000 description 2
-1 squalene peroxides Chemical class 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229960003604 testosterone Drugs 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
229960001727 tretinoin Drugs 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000008294 cold cream Substances 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000003325 follicular Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940075529 glyceryl stearate Drugs 0.000 description 1
210000004209 hair Anatomy 0.000 description 1
210000003780 hair follicle Anatomy 0.000 description 1
235000008216 herbs Nutrition 0.000 description 1
ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
229960004068 hexachlorophene Drugs 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
150000002681 magnesium compounds Chemical class 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
229960004023 minocycline Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000001782 photodegradation Methods 0.000 description 1
230000036211 photosensitivity Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
238000007788 roughening Methods 0.000 description 1
235000021003 saturated fats Nutrition 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000009131 signaling function Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
244000005714 skin microbiome Species 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
231100000378 teratogenic Toxicity 0.000 description 1
230000003390 teratogenic effect Effects 0.000 description 1
229940072172 tetracycline antibiotic Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003860 topical agent Substances 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
150000002266 vitamin A derivatives Chemical class 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Landscapes

Cosmetics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2963110A 2016-09-06 2017-04-04 Methode d'administration de sulfate de chrome et de magnesium en vue du traitement de l'acnee Pending CA2963110A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15/257,861 US9642877B1 (en)	2016-01-06	2016-09-06	Method of administration of chromium and magnesium sulfate for treatment of acne
US15257861		2016-09-06

Publications (1)

Publication Number	Publication Date
CA2963110A1 true CA2963110A1 (fr)	2018-03-06

Family

ID=61616355

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2963110A Pending CA2963110A1 (fr)	2016-09-06	2017-04-04	Methode d'administration de sulfate de chrome et de magnesium en vue du traitement de l'acnee

Country Status (1)

Country	Link
CA (1)	CA2963110A1 (fr)

2017
- 2017-04-04 CA CA2963110A patent/CA2963110A1/fr active Pending

Publication	Publication Date	Title
US20080038219A1 (en)	2008-02-14	Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof
CN1547475B (zh)	2010-12-15	含电子转移试剂的磷酸酯衍生物的皮肤制剂
EP2691077B1 (fr)	2018-05-09	Preparation topique contenant de l'acide salicylique
US11684567B2 (en)	2023-06-27	Compositions and methods for treating an infection
US20050137164A1 (en)	2005-06-23	Diclofenac compositions for the treatment of skin disorders
CN102048724A (zh)	2011-05-11	用于治疗皮肤的过氧化苯甲酰组合物
EP1625844A1 (fr)	2006-02-15	Composition a usage externe administree par voie percutanee
Olsen	1982	Therapy of acne
Draelos et al.	2016	Novel retinoid ester in combination with salicylic acid for the treatment of acne
JP2014516962A (ja)	2014-07-17	皮膚疾患の処置のための組成物及び方法
US20140199413A1 (en)	2014-07-17	Melatonin and an antimicrobial or antibacterial agent for the treatment of acne
Milton et al.	1989	Treatment of nevus comedonicus with ammonium lactate lotion
WO2012138441A1 (fr)	2012-10-11	Composition et procédé pour le traitement topique de lésions cutanées
HK1223297A1 (en)	2017-07-28	Topical retinoid solutions
US5667790A (en)	1997-09-16	Aluminum chlorhydrate as a treatment for acne and rosacea
US9642877B1 (en)	2017-05-09	Method of administration of chromium and magnesium sulfate for treatment of acne
Sánchez-Regaña et al.	2013	Compounding as a current therapeutic option in dermatology
EP2046273A2 (fr)	2009-04-15	Agents thérapeutiques rincables pour le traitement de la peau
Draelos et al.	2008	The effect of vehicle formulation on acne medication tolerability
CA2963110A1 (fr)	2018-03-06	Methode d'administration de sulfate de chrome et de magnesium en vue du traitement de l'acnee
JP2024516652A (ja)	2024-04-16	過酸化ベンゾイルおよびアゼライン酸を含む外用剤およびその使用
US10022348B2 (en)	2018-07-17	Topical solution of isotretinoin
Wilson	1989	Acne vulgaris
EP1752132A2 (fr)	2007-02-14	Compositions cosmétiques pour la peau
El Qader Toama et al.	2021	Modalities in acne vulgaris treatment